Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
29.4%
operating margin TTM
20.69%
revenue TTM
63.90 Million
revenue per share TTM
0.99$
valuation ratios | |
|---|---|
| pe ratio | 118.79 |
| peg ratio | -0.14 |
| price to book ratio | 11.34 |
| price to sales ratio | 33.00 |
| enterprise value multiple | 113.67 |
| price fair value | 11.34 |
profitability ratios | |
|---|---|
| gross profit margin | 99.86% |
| operating profit margin | 20.69% |
| pretax profit margin | 29.91% |
| net profit margin | 29.4% |
| return on assets | 9.36% |
| return on equity | 12.03% |
| return on capital employed | 6.88% |
liquidity ratios | |
|---|---|
| current ratio | 21.71 |
| quick ratio | 21.71 |
| cash ratio | 11.30 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 17.37 |
| days of payables outstanding | 3,102.05 |
| cash conversion cycle | -3,084.69 |
| receivables turnover | 21.02 |
| payables turnover | 0.12 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | 0.00 |
| cash flow to debt ratio | 14.24 |
cash flow ratios | |
|---|---|
| free cash flow per share | 2.00 |
| cash per share | 11.87 |
| operating cash flow per share | 1.99 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | 14.24 |
| short term coverage ratios | 54.76 |
| capital expenditure coverage ratio | 134.56 |
Frequently Asked Questions
When was the last time Protagonist Therapeutics, Inc. (NASDAQ:PTGX) reported earnings?
Protagonist Therapeutics, Inc. (PTGX) published its most recent earnings results on 05-08-2026.
What is Protagonist Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)'s trailing twelve months ROE is 12.03%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Protagonist Therapeutics, Inc. (PTGX) currently has a ROA of 9.36%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did PTGX's net profit margin stand at?
PTGX reported a profit margin of 29.4% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is PTGX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 21.71 in the most recent quarter. The quick ratio stood at 21.71, with a Debt/Eq ratio of 0.01.